Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks.
The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.
Turner
M S
MS
Department of Pharmacy, Moses Cone Health System, Greensboro, NC 27710, USA.
May
D B
DB
Arthur
R R
RR
Xiong
G L
GL
D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D017367:Selective Serotonin Reuptake Inhibitors